



Akums

# Namashkaar!



## नमस्कार

**Light Within Us  
Bows To The  
Light Within You**



## Our New Product Pipeline – Cephalosporin's & Penicillin Products



Cephalosporin's & Penicillin range dosages Tablets, Hard Gelatin Capsules, Dry Syrups and Dry Powder Injection

## Our New Product Pipeline - Cephalosporin's & Penicillin Products



S. No.	Product Name	Strength	Dosages form	Therapeutic class	Innovator details	Product Current Status
1	Cefixime Tablet 400 mg	400 mg	Tablet	Antibiotic	Tricef 400 mg film-coated tablets	Dossier will ready by Q2 2026 for Europe /UK / Canada Market
2	Ceftazidime	1gm &2gm	Powder for solution for injection	Antibiotic	Ceftazidime Accord 1 g powder for solution for infusion Ceftazidime Accord 2 g powder for solution for infusion	Dossier will ready by Q3 2026 for Europe /UK / Canada Market
3.	Pivmecillinam	200 mg 400 mg	Tablets	Antibiotic	Selexid 200 mg & 400 mg	Dossier will ready by Q3 2026 for Europe /UK / Canada Market
4.	Flucloxacillin	500 mg 1000 mg	Tablets	Antibiotic	Flucloxacillin 500 mg Film-coated Tablets Flucloxacillin 1000 mg Film- coated Tablets	Dossier will ready by Q3 2026 for Europe /UK / Canada Market
5.	Phenoxymethylpe nicillin	250 mg/ml	Granules for Oral Solution	Antibiotic	Phenoxymethylpenicillin Sugar Free 250mg/5ml Powder for Oral solution	Dossier will ready by Q3 2026 for Europe /UK / Canada Market

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

## Our New Product Pipeline - Cephalosporin's & Penicillin Products



S. No.	Product Name	Strength	Dosages form		Therapeutic class	Product Current Status
6.	Amoxicillin and Potassium Clavulanate Tablets	625mg (500 mg/125mg)	Tablets	Augmentin 500 mg/125 mg film-coated tablets	Antibiotic	Dossier will ready by Q3 2026 for Europe /UK / Canada Market
7.	Amoxicillin and Potassium Clavulanate Tablets	1000 mg (875mg + 125mg)	Tablets	Augmentin 875 mg/125 mg Filmtabletten	Antibiotic	Dossier will ready by Q3 2026 for Europe /UK / Canada Market
8.	Amoxicillin and Potassium Clavulanate Tablets	375mg (250 mg+125mg)	Tablets	Augmentin 250 mg/125 mg film-coated tablet	Antibiotic	Dossier will ready by Q3 2026 for Europe /UK / Canada Market

*Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.*

# Our New Oncology liquid Product Pipeline



Oncology liquid Product

## Our New Oncology liquid Product Pipeline



S. No.	Products Name	Strength	Dosages form	Therapeutic class	Innovator details	Product Current Status
1.	Hydroxyurea/Hydroxycarbamide Oral Suspension	100 mg /1 ml	Oral solution	Sickle Cell Anaemia/ Anti Cancer	Xromi 100 mg/ml oral solution Mfg. :Nova Laboratories Limited , United Kingdom	Dossier will ready by Q1 26 for Europe / ROW Market
2.	Azathioprine Oral Suspension Each ml of suspension contains 10 mg azathioprine.	10 mg/ml	Oral Solution	Anti Cancer	Jayempi 10 mg/ml oral suspension Mfg. Lipomed GmbH	Under R&D development
3.	Tamoxifen Citrate Oral Solution Each 5ml dose of oral solution contains tamoxifen 10mg (as tamoxifen citrate)	10mg/5ml	Oral Solution	Anti Cancer	Tamoxifen Rosemont 10mg/5ml Oral Solution Mfg. Rosemont Pharmaceuticals Ltd	Under R&D development
4	Methotrexate 2mg/ml 1 ml of solution contains 2 mg methotrexate.	2MG/ML	Oral Solution	Anti Cancer	Jylamvo 2 mg/ml oral solution Mfg. a Fine House S.A.	Under R&D development
5.	Mercaptopurine 20mg/ml 1 ml of suspension contains 20 mg mercaptopurine monohydrate.	20mg/ml	Oral Solution	Anti Cancer	Xaluprine 20 mg/ml oral suspension Mfg. Pronav Clinical Ltd.	Under R&D development

Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.

## Our New Oncology liquid Product Pipeline



S. No.	Products Name	Strength	Dosages form	Therapeutic class	Product Current Status
6.	Imatinib Oral Solution	400mg/5ml	Oral Solution	Anti Cancer	Under R&D development
7.	Cabozantib Oral Solution	10mg /ml	Oral solution	Renal cell Carcinoma Hepatocellular cancer	Under R&D development
8.	Nilotinib Oral Solution	50/ml	Oral Solution	Chronic Myeloid Leukemia	Under R&D development
9.	Lenvatinib Oral Solution	2mg /ml	Oral solution	Thyroid cancer , Renal cell carcinoma	Under R&D development

*Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.*

# Our New Oncology OSD Product Pipeline



S. No.	Products Name	Strength	Dosages form	Innovator details	Indication	Product Current Status
1.	Ibrutinib Tablets	140 mg, 280 mg, 420 mg, 560 mg	Tablets	IMBRUVICA 140 mg, IMBRUVICA 280 mg, IMBRUVICA 420 mg, IMBRUVICA 560 mg	Treat lymphocytic leukemia	Under R&D development
2.	Palbociclib Tablets	75 mg, 100 mg, 125 mg	Tablets	IBRANCE 75 mg, IBRANCE 100 mg, IBRANCE 125 mg	Breast cancer	Under R&D development
3.	Olaparib Tablets	100 mg, 150 mg	Tablets	Lynparza 100 mg, Lynparza 150 mg	Prostate cancer	Under R&D development
4.	Regorafenib Tablets	40 mg	Tablets	Stivarga 40 mg	Treat metastatic cancer	Under R&D development

*Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.*

## Our New Oncology OSD Product Pipeline



S. No.	Products Name	Strength	Dosages form	Innovator details	Indication	Product Current Status
5.	Nilotinib Capsule	50 mg, 150 mg, 200 mg	Capsule	Tasigna® 50 mg HG capsules, Tasigna® 150 mg HG capsules, Tasigna® 200 mg HG capsules	Treat certain types of chronic myeloid leukemia	Under R&D development
6.	Abemaciclib Tablets	50 mg, 100 mg, 150 mg	Tablets	Verzenio 50, Verzenio 100, Verzenio 150	Treat certain types of breast cancer	Under R&D development
7.	Venetoclax Tablets	10 mg, 50 mg, 100 mg	Tablets	Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg	Lymphocytic leukemia	Under R&D development
8.	Trametinib Tablets	0.5mg, 2mg	Tablets	Mekinist® 0.5 mg Mekinist® 2 mg	Treat certain types of melanoma (a type of skin cancer)	Under R&D development
9.	Enzalutamide Tablets	40 mg & 80 mg	Tablets	XTANDI (Enzalutamide)	Treat castration-resistant prostate cancer	Under R&D development

*Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.*

# Our New Oncology OSD Product Pipeline



S. No.	Products Name	Strength	Dosages form	Innovator details	Indication	Product Current Status
10.	Cabozantinib Tablets	20mg, 40 mg, 60 mg	Tablets	Cabometyx Tablets (Cabozantinib)	treat advanced kidney cancer	Under R&D development
11	Elacestrant Tablets	86 mg (Base), 345 mg (Base)	Tablets	Orserdu tablets (Elacestrant Tablets)	treat certain types of hormone receptor-positive breast cancer	Under R&D development
12	Apalutamide Tablets	60 mg, 240 mg	Tablets	Erleada Tablets (Apalutamide)	treat patients with metastatic castration-sensitive prostate cancer	Under R&D development
13	Osimertinib Tablets	40 mg & 80 mg	Tablets	TAGRISO Tablets (Osimertinib)	treat non-small cell lung cancer (NSCLC)	Under R&D development
14	Ruxolitinib Tablets	5mg, 10 mg, 15mg, 20 mg	Tablets	Jakavi tablets (Ruxolitinib)	treat myelofibrosis	Under R&D development
15	Dabrafenib Capsules	50 mg & 75 mg	Capsules	Tafinlar Capsules (Dabrafenib)	treat melanoma	Under R&D development

*Products which are subject to patent protection are currently not offered or made available in countries where patent are in force.*



# Namaste



The light within us bows to  
the Light within you

# Thank You